Shota Fukuoka

PD-1 ⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

Takahiro Kamada, Yosuke Togashi, Christopher Tay et al. · Proceedings of the National Academy of Sciences · 2019 · 987 citations · Full text

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 887 citations · Full text

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai, Yosuke Togashi, Takahiro Kamada et al. · Nature Immunology · 2020 · 785 citations

Cancer Immunosurveillance, Autoimmune Disease, T-regulatory Cell +12

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Shogo Kumagai, Shohei Koyama, Kota Itahashi et al. · Cancer Cell · 2022 · 752 citations

Cancer Immunosurveillance, Pd-1 Expression, Medicine +11

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura et al. · The Lancet Oncology · 2020 · 258 citations

Gastrointestinal Oncology, Advanced Gastric Cancer, Medicine +8